Free Trial

Oxford BioMedica (OTCMKTS:OXBDF) Shares Gap Down - Should You Sell?

Oxford BioMedica logo with Medical background

Key Points

  • Oxford BioMedica's shares gapped down at the start of trading on Tuesday, opening at $6.08 after closing at $6.30 the previous day.
  • The stock last traded at $6.26 with a trading volume of 500 shares, while the company's 50-day and 200-day moving averages are $4.93 and $4.40, respectively.
  • Oxford BioMedica specializes in gene delivery systems through its advanced LentiVector platform technology, aimed at improving safety and delivery compared to previous vector systems.
  • Need better tools to track Oxford BioMedica? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Oxford BioMedica (OTCMKTS:OXBDF - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $6.30, but opened at $6.08. Oxford BioMedica shares last traded at $6.26, with a volume of 500 shares changing hands.

Oxford BioMedica Stock Performance

The company's 50-day moving average price is $4.93 and its 200-day moving average price is $4.40.

Oxford BioMedica Company Profile

(Get Free Report)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oxford BioMedica Right Now?

Before you consider Oxford BioMedica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford BioMedica wasn't on the list.

While Oxford BioMedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines